CAP TODAY Pathology/Laboratory Medicine/Laboratory Management
June 2017—ArcherDx and precision medicine company HeliTec (Shenzhen, China) announced a strategic partnership to advance NGS-based cancer diagnostic development in China. The partnership will entail co-developing and cross-licensing NGS-based technologies with the goal of registering oncology diagnostic kits with the Chinese Food and Drug Administration.
“We are pleased to work with Archer to co-develop cutting-edge, NGS-based diagnostic assays in China, particularly on those cancer types predominant in Asian populations,” Dongbin Zhou, CEO of HeliTec, said in a statement. “AMP technology has been widely adopted for a number of cancer sequencing applications, and this collaboration will bring a complete pipeline of AMP-based assays to the Chinese clinical market.”
All Archer NGS assays, including FusionPlex RNA assays, VariantPlex DNA assays, the Reveal ctDNA 28 kit, and the Immunoverse T-cell receptor kit, are available from HeliTec.
ArcherDx, 303-357-9001